Clinical Benefit From Molecularly Guided Cancer Care: A Matching-Adjusted Indirect Comparison of Larotrectinib Versus Standard of Care Four of 35 (11%; 95% CI, 3.2 to 26.7) HRP and four of 12 HRRm ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback